Literature DB >> 14504188

Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study.

Steven Siu-lung Li1, Cheung-wah Cheng, Chiu-lai Fu, Yiu-han Chan, Man-po Lee, Johnny Wai-man Chan, Siu-fung Yiu.   

Abstract

BACKGROUND: Severe acute respiratory syndrome (SARS) is characterized by an overaggressive immune response. Myocardial performance may be impaired in cytokine-mediated immune reactions. METHODS AND
RESULTS: Forty-six patients with established clinical diagnosis of SARS were studied prospectively. Transthoracic echocardiographic examinations were done at the acute stage of infection and 30 days later. Among them, 14 patients required mechanical ventilation. The clinical course, laboratory data, SARS-CoV antibody titers, and results of reverse transcriptase-polymerase chain reaction were studied. Significantly higher left ventricular index of myocardial performance (IMP) (0.42+/-0.13 versus 0.33+/-0.09, P<0.001), longer isovolumic relaxation time (102.9+/-15.7 versus 81.6+/-14.7 ms, P<0.001), lower flow propagation velocity (69.6+/-15.7 versus 83.8+/-19.7 cm/s, P=0.011), and Doppler-derived cardiac output (4.69+/-1.01 versus 5.49+/-1.04 L/min, P<0.001) were observed during acute infection when compared with those at 30 days. No significant valvular disease or pulmonary hypertension was found. At baseline, a lower mean left ventricular ejection fraction (LVEF) (65.3+/-12.8% versus 71.4+/-5.7%, P=0.03) and a higher mean IMP (0.51+/-0.11 versus 0.40+/-0.12, P=0.017) were found in patients who required mechanical ventilation. A decrease in LVEF correlated moderately with an elevated lactate dehydrogenase level (r=-0.605, P<0.001), whereas a higher IMP correlated weakly with an increase in creatine kinase level (r=0.38, P=0.016). Histological examination of the heart in the patient with the lowest EF (30.2%) revealed no interstitial lymphocytic infiltrate or myocyte necrosis.
CONCLUSIONS: Subclinical diastolic impairment without systolic involvement was observed in patients with SARS. This impairment may be reversible on clinical recovery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504188     DOI: 10.1161/01.CIR.0000094737.21775.32

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

Review 1.  Severe acute respiratory syndrome (SARS): epidemiology and clinical features.

Authors:  D S C Hui; M C H Chan; A K Wu; P C Ng
Journal:  Postgrad Med J       Date:  2004-07       Impact factor: 2.401

2.  Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients.

Authors:  Alvaro Lorente-Ros; Juan Manuel Monteagudo Ruiz; Luis M Rincón; Rodrigo Ortega Pérez; Sonia Rivas; Rafael Martínez-Moya; Maria Ascensión Sanromán; Luis Manzano; Gonzalo Luis Alonso; Borja Ibáñez; Jose Luis Zamorano
Journal:  Cardiol J       Date:  2020-06-26       Impact factor: 2.737

3.  Longer term follow up of aerobic capacity in children affected by severe acute respiratory syndrome (SARS).

Authors:  C C W Yu; A M Li; R C H So; A McManus; P C Ng; W Chu; D Chan; F Cheng; W K Chiu; C W Leung; Y S Yau; K W Mo; E M C Wong; A Y K Cheung; T F Leung; R Y T Sung; T F Fok
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

4.  Covid-19 Effects on ARTErial StIffness and Vascular AgeiNg: CARTESIAN Study Rationale and Protocol.

Authors:  Rosa Maria Bruno; Bart Spronck; Bernhard Hametner; Alun Hughes; Patrick Lacolley; Christopher C Mayer; Maria Lorenza Muiesan; Chakravarthi Rajkumar; Dimitrios Terentes-Printzios; Thomas Weber; Tine Willum Hansen; Pierre Boutouyrie
Journal:  Artery Res       Date:  2020       Impact factor: 0.597

Review 5.  Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection.

Authors:  Vincent C C Cheng; Susanna K P Lau; Patrick C Y Woo; Kwok Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

6.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

7.  Manifestation of cardiac injury in hospitalised patients with COVID-19.

Authors:  Huolan Zhu; Yanfei Zhang; Zuowei Pei; Ying Guo; Chenguang Yang; Yan Song; Xiaomei Guo; Fang Wang
Journal:  Int J Clin Pract       Date:  2021-04-12       Impact factor: 3.149

8.  Major cardiac concerns in therapy and vaccinations for COVID-19.

Authors:  Syam Sundar Junapudi; Sunil Junapudi; Kishore Ega; Bojjibabu Chidipi
Journal:  Metabol Open       Date:  2021-06-29

Review 9.  Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19.

Authors:  Rhian M Touyz; Marcus O E Boyd; Tomasz Guzik; Sandosh Padmanabhan; Linsay McCallum; Christian Delles; Patrick B Mark; John R Petrie; Francisco Rios; Augusto C Montezano; Robert Sykes; Colin Berry
Journal:  CJC Open       Date:  2021-06-16

Review 10.  Comparison of the cardiovascular presentations, complications and outcomes following different coronaviruses' infection: A systematic review.

Authors:  Mohammad Mostafa Ansari Ramandi; Hossein Yarmohammadi; Somayeh Beikmohammadi; Behzad Hassan Hosseiny Fahimi; Farbod Hatami; Hossein Beydokhti; Hooman Bakhshandeh; Nasim Naderi
Journal:  J Cardiovasc Thorac Res       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.